STOCK TITAN

ICON PLC Stock Price, News & Analysis

ICLR Nasdaq

Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.

ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.

Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.

Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.

Rhea-AI Summary
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced its Q2 2025 earnings release schedule. The company will disclose its financial results after market close on Wednesday, July 23, 2025. A conference call and webcast to discuss the results will be held the following day, Thursday, July 24, 2025, at 8:00am ET. Investors can access the live webcast through the Events section of ICON's Investor Relations website. A replay of the webcast will be made available approximately one hour after the call concludes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences earnings
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced that its CEO, Dr. Steve Cutler, will present at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for Wednesday, June 4, 2025, at 10:40 AM CT. The company will provide updates and links to the live webcast, where available, on the Investor section of their website under the "Events" tab.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
conferences
-
News
Rhea-AI Summary

ICON (NASDAQ: ICLR) has released its ICON Cares 2024 Report, highlighting significant achievements in environmental, social, and governance (ESG) goals. The company received a 72/100 score from EcoVadis (silver medal) and a B- score on CDP Climate Change response. In 2024, ICON supported over 1,270 clinical studies involving more than 416,000 patients, contributing to 19 medicine approvals.

Notable environmental achievements include exceeding their near-term SBTi target with a 70.06% reduction in Scope 1 & 2 GHG emissions, achieving 84.67% renewable electricity consumption, and reducing laboratory kit wastage by 15-20%. The company expanded its AI and robotic process automation capabilities while strengthening governance protocols.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) has released findings from a survey of 155 biotech and pharma professionals regarding multi-indication cardiometabolic R&D for obesity therapies. The survey reveals that 83% of sponsors are pursuing multi-indication approaches in obesity research, but many underestimate the complexity of these strategies.

Key findings show that 90% of respondents are not implementing non-traditional study arms like master protocols, while only 14% pursue multiple indications based on longitudinal data. Furthermore, only 19% follow patients for more than three years. Despite these challenges, 77% of respondents believe multi-indication R&D would lower healthcare costs.

In response, ICON has launched their new Centre for Obesity, featuring an infrastructure of 100 sites and a developing database of 10,000 pre-screened patients across obesity-related comorbidities to facilitate rapid multi-indication research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
-
News
Rhea-AI Summary

ICON reported mixed Q1 2025 financial results with net business wins of $2,022 million and a book-to-bill ratio of 1.01. Revenue decreased 4.3% year-over-year to $2,001.3 million, while adjusted EBITDA was $390.7 million (19.5% of revenue).

Key highlights include:

  • Closing backlog of $24.7 billion, up 6.0% from Q1 2024
  • GAAP net income of $154.2 million ($1.90 per diluted share)
  • Adjusted net income of $258.3 million ($3.19 per diluted share)
  • Net debt of $2.9 billion with a net debt to adjusted EBITDA ratio of 1.7x

The company updated its 2025 guidance, now expecting revenue between $7,750-$8,150 million (representing -6.4% to -1.6% YoY) and adjusted EPS of $12.75-$14.25. Performance was impacted by market volatility, customer decision delays, and elevated cancellations. The company repurchased $250 million worth of stock at an average price of $184.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) has scheduled its first quarter 2025 earnings release and conference call. The company will release its Q1 2025 financial results after market close on Wednesday, April 30, 2025. A conference call and webcast to discuss the results will be held the following day on Thursday, May 1, 2025 at 8:00am ET. A webcast replay will be available approximately one hour after the call concludes. Any updates or changes to these events will be posted on the Investor section of ICON's website under 'Events'.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
conferences earnings
Rhea-AI Summary

BetterInvesting Magazine has selected Lowe's Cos. (NYSE: LOW) as its 'Stock to Study' for the June/July 2025 double issue, suggesting the stock warrants further investigation from a valuation perspective. The magazine provides comprehensive fundamental data including sales, earnings, pre-tax profit, and return on equity through the National Association of Investors platform.

Additionally, the publication's Editorial Advisory and Securities Review Committee has identified ICON PLC (NASDAQ: ICLR) for fundamental review in the same issue, specifically from an undervalued perspective. The committee's analysis is conducted by six CFA-qualified members.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
-
Rhea-AI Summary

ICON (NASDAQ: ICLR) has become the first large Clinical Research Organization to fully integrate Medidata Clinical Data Studio into its clinical workflows. This strategic implementation allows ICON to leverage AI-powered technology for unified data management across Medidata and non-Medidata sources.

The integration enhances ICON's ability to streamline data review, central monitoring, and medical review processes through AI and statistical modeling. This advancement is particularly significant for ICON's Clinical Data Science group, which specializes in risk-based quality management.

The partnership builds on a 20-year relationship between ICON and Medidata, during which they have collaborated on more than 1,700 studies, with over 400 currently active studies across various therapeutic areas including oncology, central nervous system, and vaccine therapies. ICON also utilizes Medidata eCOA and Medidata Designer for clinical operations management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, has announced upcoming presentations at two major healthcare investor conferences. Dr. Steve Cutler, CEO of ICON plc, is scheduled to present at:

  • The Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:00 am ET
  • The Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025, at 8:30 am ET

Any updates to these events and live webcast links will be available in the Investor section of ICON's website under 'Events'.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences
Rhea-AI Summary

ICON plc (NASDAQ: ICLR) and Mural Health Technologies have announced a strategic partnership to implement Mural Link, a comprehensive participant management and payments platform for clinical trials. The collaboration aims to enhance trial participation experience and efficiency.

Through this partnership, ICON will leverage Mural Link's features including:

  • Clinical trial participant payment systems
  • Tax management capabilities
  • Travel and concierge support
  • Site-participant communication tools
  • Advanced reporting and analytics

A key highlight is Mural Health's fee-free debit card option, designed to eliminate financial barriers to trial participation. The partnership focuses on increasing the recruitable patient population, particularly among historically underrepresented groups, while reducing participant-level operational challenges that contribute to patient attrition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
partnership clinical trial

FAQ

What is the current stock price of ICON PLC (ICLR)?

The current stock price of ICON PLC (ICLR) is $150.863 as of July 2, 2025.

What is the market cap of ICON PLC (ICLR)?

The market cap of ICON PLC (ICLR) is approximately 11.6B.
ICON PLC

Nasdaq:ICLR

ICLR Rankings

ICLR Stock Data

11.60B
78.96M
0.61%
98.56%
2.09%
Diagnostics & Research
Healthcare
Link
Ireland
Dublin